Jay Ciezki is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 281 publications with 9,530 citations (h-index 39); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 441950001
Telephone
800-223-2273Registry record last updated 25 Jan 2008.
Clinical trials
- Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Sponsor: Case Comprehensive Cancer Center
- Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma
Sponsor: The Cleveland Clinic
- Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- IsoRay, IncProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
86.7%alpha-Adrenergic Blocker83.5%Tamsulosin Hcl95%Alfuzosin Hcl Er5%Part D≥309 patientsCholinergic Muscarinic Antagonist3.2%Oxybutynin Chloride Er100%Part D≥19 patientsSensory organs
12.5%Fluoroquinolone Antibacterial12.5%Ciprofloxacin Hcl100%Part D≥171 patientsCardiovascular
0.9%alpha-Adrenergic Blocker0.9%Doxazosin Mesylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Serpil Erzurum, MD
Cleveland Clinic
Arthur McCullough, MD
Cleveland Clinic
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”